SecBot SecBot
DEFA14A ·Filed Mar 13, 2026

HCA

HCA Healthcare, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed8mo ago SEC0001193125-26-106153
Proxy solicitation materials
Actionable Insight • Neutral

This is a standard, routine filing. Traders should note the board's unanimous recommendation for all management proposals and the opposition to the shareholder proposals. The lack of any contested director elections or significant governance issues suggests stability in the company's leadership, which may be viewed as a neutral factor for long-term investors.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$525.04
T+0 close · Mar 13, 2026 · via day close
Latest settled
−31.18%
T+60 · $361.32
Vs SPY
−41.67%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 16 $525.04entry
  2. T+1 · 8mo ago −2.93%α −3.20% · $509.67
  3. T+5 · 8mo ago −5.82%α −3.78% · $494.47
  4. T+20 · 7mo ago −5.39%α −9.17% · $496.74
  5. T+60 · 5mo ago −31.18%α −41.67% · $361.32
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HCA Healthcare has filed its definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, scheduled for April 23, 2026. The filing outlines the board's recommendations for shareholder votes on the election of nine director nominees, the ratification of Ernst & Young as the independent auditor, an advisory vote on executive compensation, and opposition to two shareholder proposals regarding a healthcare consequences report and shareholder rights to act by written consent.

Key Facts

  • The filing is a definitive proxy statement (DEFA14A) for HCA Healthcare's 2026 Annual Meeting.
  • The meeting is scheduled for April 23, 2026, and voting must be completed by April 22, 2026.
  • The board recommends voting 'For' the election of all nine director nominees: Thomas F. Frist III, Samuel N. Hazen, John W. Chidsey, III, Nancy-Ann DeParle, William R. Frist, Hugh F. Johnston, Michael W. Michelson, Wayne J. Riley, M.D., and Andrea B. Smith.
  • The board recommends voting 'For' the ratification of Ernst & Young LLP as the independent auditor.
  • The board recommends voting 'For' the advisory vote to approve named executive officer compensation.
  • The board recommends voting 'Against' two shareholder proposals: one on a report on healthcare consequences and another on shareholder rights to act by written consent.

Financial Impact

None. This is a routine procedural filing with no direct financial impact.

Risk Factors

  • None identified. This is a routine, non-material filing.

Market Snapshot

Exchange
NYSE

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-106153
Document: 0001193125-26-106153-index-headers.html0001193125-26-106153
Document: 0001193125-26-106153-index.html0001193125-26-106153
Document: 0001193125-26-106153.txt0001193125-26-106153

US Market Status

Market Closed · Opens in 8h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 13, 2026